Revlimid To Launch With Risk Management Plan; Restrictions Could Be Lifted
Executive Summary
Celgene's Revlimid will launch under the risk management plan RevAssist to minimize fetal exposure, but the firm may lift the program if ongoing studies demonstrate there is no risk of teratogenicity
You may also be interested in...
Revlimid Cleared For Multiple Myeloma; Celgene Focuses On Thrombotic Risk
Celgene hopes to submit data to FDA showing that thromboembolic risks linked to Revlimid (lenalidomide) can be reduced with prophylactic anticoagulant use
Revlimid Cleared For Multiple Myeloma; Celgene Focuses On Thrombotic Risk
Celgene hopes to submit data to FDA showing that thromboembolic risks linked to Revlimid (lenalidomide) can be reduced with prophylactic anticoagulant use
FDA’s Rx/Dx Co-Development Approach Overlooks Incentives – Novartis Exec
FDA's concept paper on drug-diagnostic co-development does not account for "practical" issues facing firms, such as incentives, Novartis Oncology Diagnostic Development Director Mark Braganza said